Experience

Hebei Normal University

• China
• Higher Education
• 1 - 100 Employee

• Professor & Director for The Center of Drug Discovery and Innovation

  • Dec 2017 - Present

  1. Start-up research center to focus on drug discovery and innovation by using State of Art Technologies for drug screening , computer based design and biological assays. 2. Close collaboration with global academic and industrial experts. 1. Start-up research center to focus on drug discovery and innovation by using State of Art Technologies for drug screening , computer based design and biological assays. 2. Close collaboration with global academic and industrial experts.



Zhangjiakou Jianlong Health Fund and Jianyuan Tech. Co. Ltd.

• Zhangjiakou, Hebei, China

• Founder

  • Dec 2017 - Present

  1. Have Raised significant funds to invest early to mid stage companies for health industry ; 2. Founder of two companies focusing on food safety testing and precision medicine products and technologies 1. Have Raised significant funds to invest early to mid stage companies for health industry ; 2. Founder of two companies focusing on food safety testing and precision medicine products and technologies



Zensun (Shanghai) Sci. & Tech. Co. ltd

• Pudong, Shanghai, China

• EXecutive VP

  • 2000 - Dec 2017

  Innovative drug development for Chronic Heart Failure and Cancer Innovative drug development for Chronic Heart Failure and Cancer



Zensun USA INC

• Greater San Diego Area

• President

  • Nov 2006 - Aug 2016

  1) Establishing Zensun USA, a wholly-owned subsidiary of its Parent Company, Zensun (Shanghai); 2) Building and overseeing core team of Zensun USA for clinical, CMC, Regulatory and QA functions; 3) Filing TGA and FDA IND for a phase 2 clinical program for the treatment of CHF; 4) Overseeing clinical trials in Australia and USA; 5) Organizing EOP2 meeting with FDA for phase 3 clinical development 1) Establishing Zensun USA, a wholly-owned subsidiary of its Parent Company, Zensun (Shanghai); 2) Building and overseeing core team of Zensun USA for clinical, CMC, Regulatory and QA functions; 3) Filing TGA and FDA IND for a phase 2 clinical program for the treatment of CHF; 4) Overseeing clinical trials in Australia and USA; 5) Organizing EOP2 meeting with FDA for phase 3 clinical development



Victor Chang Cardiac Research Institute

• Australia
• Research
• 100 - 200 Employee

• Postdoc/Senior Research Officer

  • Jul 1996 - Nov 2000